Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Study ID
- NCT01044329
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Branch Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUGIntravitreal, 1.25 mg, 3 times, one month apart.
- Triamcinolone Acetonide — DRUGIntravitreal, 2 mg, 2 times, two months apart.
Study Details
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Key Dates
- First listed
- Jan 7, 2010
- Start date
- Jan 31, 2010
- Status verified
- Jan 2010
- Primary completion
- Aug 31, 2010
- Completion
- Dec 31, 2010
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Intravitreal bevacizumab
- Active Comparator: Intravitreal triamcinolone
Primary Outcome Measure
Visual acuity [ Time Frame: 6 months ]